main 2310, LLC

p.o. box 245
esses, new york 12936

NYS Entity Status
ACTIVE

NYS Filing Date
JUNE 12, 2013

NYS DOS ID#
4416678

County
ESSEX

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - MAIN 2310, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy VC, Deals, & Startups Feed
  • NYPD public service campaign tells drug users to call 911 when they overdose
    By Associated Press - Wednesday Jun 21, 2017

    A New York Police Department public service campaign aims to alert drug users—and witnesses—that they won't be arrested if they call 911 during an overdose emergency.The campaign will...

    To view the full story, click the title link.

    Source: Crain&apso;s New York Business
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed